Polling suggests that concerns about corruption and healthcare costs are top of mind for most voters as Election Day approaches. A Fox News poll released this week showed large majorities of voters listed both in the top five issues they were “extremely” or “very” concerned about. A new report about President Donald Trump’s self-enrichment by way of the pharmaceutical industry underscores the uniquely awful political predicament Republicans have created for themselves by wedding their party to one of the most corrupt administrations in American history.

Democrats on the Joint Economic Committee previously spotlighted the ways that Trump’s stock investments in the oil and gas industries have benefited from his destructive geopolitical agenda, including his deadly war with Iran. Now, the committee is out with a new report on the ways Trump’s stock investments in the pharmaceutical industry have benefited from provisions of the (ridiculously) so-called One Big Beautiful Bill Act that Republicans forced through last year.

According to the new report:

As Americans face sky-high health care costs, President Trump and Congressional Republicans passed into law last year a new giveaway to Big Pharma that enables many pharmaceutical companies to keep charging seniors exorbitant prices for cancer treatments and other medications. This measure — which blocks the Medicare program from negotiating lower prices for several high-cost drugs — will add around $9 billion to the deficit.

The report cites financial disclosure forms that show that in 2025, “Trump held as much as $39.1 million in stock in the same Big Pharma companies that directly benefited from the giveaway that he and Congressional Republicans devised.” And that “these companies reported at least $54 billion in U.S. sales of drugs that benefitted from the carveout in 2025, a 13 percent increase from the year before.”

Trump has made more stock trades since returning to office than everyone in Congress combined. The White House has routinely said that these trades are handled by third parties over which Trump has no influence, denying allegations of corruption or conflicts of interest.

But it seems the majority of Americans aren’t convinced that the self-described “freaking genius” president has truly extricated his personal business dealings from industries that benefit from his policies: A recent AP-NORC poll found that 60% of adults think Trump has either illegally or unethically profited from the presidency.

The post The ‘One Big Beautiful Bill’ opened the door to benefit Big Pharma — and Trump appeared first on MS NOW.

Author: Source Author

From MS Now.